These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 37822079)

  • 1. Lethal immunotoxicity in high-dose systemic AAV therapy.
    Duan D
    Mol Ther; 2023 Nov; 31(11):3123-3126. PubMed ID: 37822079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy.
    Duan D
    Mol Ther; 2018 Oct; 26(10):2337-2356. PubMed ID: 30093306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspective on Adeno-Associated Virus Capsid Modification for Duchenne Muscular Dystrophy Gene Therapy.
    Nance ME; Duan D
    Hum Gene Ther; 2015 Dec; 26(12):786-800. PubMed ID: 26414293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Full-length dystrophin restoration via targeted exon integration by AAV-CRISPR in a humanized mouse model of Duchenne muscular dystrophy.
    Pickar-Oliver A; Gough V; Bohning JD; Liu S; Robinson-Hamm JN; Daniels H; Majoros WH; Devlin G; Asokan A; Gersbach CA
    Mol Ther; 2021 Nov; 29(11):3243-3257. PubMed ID: 34509668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the Gene Therapy Immune Response in the Canine Muscular Dystrophy Model.
    Hakim CH; Kumar SRP; Pérez-López D; Teixeira J; Herzog RW; Duan D
    Methods Mol Biol; 2023; 2587():353-375. PubMed ID: 36401038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models.
    Hakim CH; Kumar SRP; Pérez-López DO; Wasala NB; Zhang D; Yue Y; Teixeira J; Pan X; Zhang K; Million ED; Nelson CE; Metzger S; Han J; Louderman JA; Schmidt F; Feng F; Grimm D; Smith BF; Yao G; Yang NN; Gersbach CA; Chen SJ; Herzog RW; Duan D
    Nat Commun; 2021 Nov; 12(1):6769. PubMed ID: 34819506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Micro-Dystrophin Gene Therapy Goes Systemic in Duchenne Muscular Dystrophy Patients.
    Duan D
    Hum Gene Ther; 2018 Jul; 29(7):733-736. PubMed ID: 29463117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy.
    Nelson CE; Wu Y; Gemberling MP; Oliver ML; Waller MA; Bohning JD; Robinson-Hamm JN; Bulaklak K; Castellanos Rivera RM; Collier JH; Asokan A; Gersbach CA
    Nat Med; 2019 Mar; 25(3):427-432. PubMed ID: 30778238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced CRISPR-Cas9 correction of Duchenne muscular dystrophy in mice by a self-complementary AAV delivery system.
    Zhang Y; Li H; Min YL; Sanchez-Ortiz E; Huang J; Mireault AA; Shelton JM; Kim J; Mammen PPA; Bassel-Duby R; Olson EN
    Sci Adv; 2020 Feb; 6(8):eaay6812. PubMed ID: 32128412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The AAV-mediated and RNA-guided CRISPR/Cas9 system for gene therapy of DMD and BMD.
    Wang JZ; Wu P; Shi ZM; Xu YL; Liu ZJ
    Brain Dev; 2017 Aug; 39(7):547-556. PubMed ID: 28390761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual AAV therapy ameliorates exercise-induced muscle injury and functional ischemia in murine models of Duchenne muscular dystrophy.
    Zhang Y; Yue Y; Li L; Hakim CH; Zhang K; Thomas GD; Duan D
    Hum Mol Genet; 2013 Sep; 22(18):3720-9. PubMed ID: 23681067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Full-length dystrophin reconstitution with adeno-associated viral vectors.
    Lostal W; Kodippili K; Yue Y; Duan D
    Hum Gene Ther; 2014 Jun; 25(6):552-62. PubMed ID: 24580018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safe and bodywide muscle transduction in young adult Duchenne muscular dystrophy dogs with adeno-associated virus.
    Yue Y; Pan X; Hakim CH; Kodippili K; Zhang K; Shin JH; Yang HT; McDonald T; Duan D
    Hum Mol Genet; 2015 Oct; 24(20):5880-90. PubMed ID: 26264580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Applications of CRISPR/Cas for Duchenne Muscular Dystrophy.
    Wong TWY; Cohn RD
    Curr Gene Ther; 2017; 17(4):301-308. PubMed ID: 29173172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual AAV Gene Therapy for Duchenne Muscular Dystrophy with a 7-kb Mini-Dystrophin Gene in the Canine Model.
    Kodippili K; Hakim CH; Pan X; Yang HT; Yue Y; Zhang Y; Shin JH; Yang NN; Duan D
    Hum Gene Ther; 2018 Mar; 29(3):299-311. PubMed ID: 28793798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The gRNA Vector Level Determines the Outcome of Systemic AAV CRISPR Therapy for Duchenne Muscular Dystrophy.
    Wasala NB; Million ED; Watkins TB; Wasala LP; Han J; Yue Y; Lu B; Chen SJ; Hakim CH; Duan D
    Hum Gene Ther; 2022 May; 33(9-10):518-528. PubMed ID: 35350865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of Therapeutic Potential of a Dual AAV Approach for Duchenne Muscular Dystrophy.
    Albini S; Palmieri L; Dubois A; Bourg N; Lostal W; Richard I
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical development on the frontier: gene therapy for duchenne muscular dystrophy.
    Asher DR; Thapa K; Dharia SD; Khan N; Potter RA; Rodino-Klapac LR; Mendell JR
    Expert Opin Biol Ther; 2020 Mar; 20(3):263-274. PubMed ID: 32031420
    [No Abstract]   [Full Text] [Related]  

  • 19. Adeno-Associated Virus (AAV) Mediated Dystrophin Gene Transfer Studies and Exon Skipping Strategies for Duchenne Muscular Dystrophy (DMD).
    Kawecka K; Theodoulides M; Hasoglu Y; Jarmin S; Kymalainen H; Le-Heron A; Popplewell L; Malerba A; Dickson G; Athanasopoulos T
    Curr Gene Ther; 2015; 15(4):395-415. PubMed ID: 26159373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene therapy for Duchenne muscular dystrophy: AAV leads the way.
    Judge LM; Chamberlain JS
    Acta Myol; 2005 Dec; 24(3):184-93. PubMed ID: 16629052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.